DOCKET NO.: DMCI-0099

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of: Daphna Havkin-Frenkel, Andrzej Podstolski, Richard A. Dixon

Serial No.: Not yet assigned

Group Art Unit: Not yet assigned

Filing Date: Herewith

Examiner: Not yet assigned

For: VANILLIN BIOSYNTHETIC PATHWAY ENZYME FROM VANILLA

PLANIFOLIA

EXPRESS MAIL LABEL NO:EL719246398US DATE OF DEPOSIT: February 28, 2002

SN9654F349RT

Box	Matent Application
	☐ Sequence ☐ Design
	tant Commissioner for Patents ington, DC 20231
Sir:	
	PATENT APPLICATION TRANSMITTAL LETTER
	Transmitted herewith for filing, please find
\boxtimes	A Utility Patent Application under 37 C.F.R. 1.53(b).
	It is a continuing application, as follows:
	☐ continuation ☐ divisional ☒ continuation-in-part of prior application number
	A Design Patent Application (submitted in duplicate).
	Request for Nonpublication is attached.

The state of the s

Including the following:

New or Revised Specification, includi

New or Revised Specification, including pages 1 to 114 containing				
	\boxtimes	Specification		
	\boxtimes	Claims		
	\boxtimes	Abstract		
		Substitute Specification, including Claims and Abstract.		
		The present application is a continuation application of Application No filed The present application includes the Specification of the parent application which has been revised in accordance with the amendments filed in the parent application. Since none of those amendments incorporate new matter into the parent application, the present revised Specification also does not include new matter. The present application is a continuation application of Application No filed, which in turn is a continuation-in-part of Application No filed The present application includes the Specification of the parent application which has been revised in accordance with the amendments filed in the parent application. Although the amendments in the parent C-I-P application may have incorporated new matter, since those are the only revisions		
		included in the present application, the present application includes no new matter in relation to the parent application.		
	includ matte for su	by of earlier application Serial NoFiled, ling Specification, Claims and Abstract (pages 1 - @@), to which no new r has been added TOGETHER WITH a copy of the executed oath or declaration ch earlier application and all drawings and appendices. Such earlier application eby incorporated into the present application by reference.		
	Please enter the following amendment to the Specification under the Cross-Refe to Related Applications section (or create such a section): "This Application:			
		a continuation of \square is a divisional of \square claims benefit of U.S. provisional		

DO	OCKET N	NO. : DMCI-0099	- 3 -		PATENT			
	Signe	Signed Statement attached deleting inventor(s) named in the prior application.						
	A Pro	eliminary Amendment.						
\boxtimes	<u>11</u>	Sheets of Forma	al Drawings.					
		Orawing view to publish	h: <u>1</u>					
	Petiti	ion to Accept Photogra	phic Drawings.					
•		Petition Fee						
4								
×	An [Executed Unexe	cuted Declaration or C	Oath and Power of	f Attorney.			
	An A	Associate Power of Atto	orney.					
	l An [An Executed Copy of Executed Assignment of the Invention to						
lines find that then	☐ A Recordation Form Cover Sheet.							
		Recordation Fee						
_	l ————————————————————————————————————							
<u></u>		prior application is assi						
<u> </u>		ity is claimed under 35						
	filed		n					
	<u></u>	claimed:	each of the above app	lications for which	ch priority is			
		is enclosed.						
			ı prior application Seri	al No	filed			
			prior application son	ar 110				
		Please enter the follo	owing amendment to the	he first sentence	of the specification			
		•	tence): "This applicati , which was j					

	DOC	KET NO. : DMCI-0099	- 4 -	PATENT			
		Applicant(s) by its/their undersited C.F.R. §1.27 as:	gned attorney, claims	small entity status under 37			
		an Independent Inventor					
		a Small Business Concern					
		a Nonprofit Organization.		•			
-	\boxtimes	Diskette Containing DNA/Amin	no Acid Sequence Info	ormation.			
	\boxtimes	Statement to Support Submission of DNA/Amino Acid Sequence Information.					
		Sequence listing containing pag	es <u>1-19</u> .				
		Application Serial Number	, filed	only computer readable form for the instant emark Office will make the te for the computer readable paper copy of the Sequence			
•		Information Disclosure Stateme Attached Form 1449. Copies of each of the reference enclosed herewith.		attached Form PTO-1449 are			
		A copy of Petition for Extension	n of Time as filed in th	ne prior case.			
		Appended Material as follows:					

DOCKET NO.: DMCI-0099	- 5 -	PATENT

\boxtimes	Return Receipt Postcard (should	be specifical	lly itemized)		
	Other as follows:				
					·
FEE (CALCULATION:				
	Cancel in this application original calculating the filing fee. (At least for filing purposes.)				
		SMALL	ENTITY	NOT SMA	ALL ENTITY
		75. 4 (77)	TIPE	D A TEXT	ner.

				SMALL	ENTITY	NOT SMA	LL ENTITY
88				RATE	FEE	RATE	FEE
DE	SIGN APPLICA	TION		\$165.00	\$	\$330.00	\$
UT	ILITY APPLICA	ATIONS BASE FE	E	\$370.00	\$	\$740.00	\$ 740.00
CA		ATION; ALL CLA FTER ENTRY OF					
		No. Filed	No. Extra				
	TOTAL CLAIMS	31 - 20 =	11	\$9 each	\$	\$18 each	\$ 198.00
	INDEP. CLAIMS	5 - 3 =	2	\$42 each	\$	\$84 each	\$ 168.00
TOTAL CLAIMS INDEP. 5 - 3 = 2 CLAIMS FIRST PRESENTATION OF MULTIPLE DEPENDENT CLAIM			\$140	\$	\$280	\$ 0.00	
	ADDITIONAL FILING FEE			\$		\$ 0.00	
TOTAL FILING FEE DUE				\$		\$ 1106.00	

\boxtimes		
	A Ch	eck is enclosed in the amount of \$\frac{1106.00}{}.
refund any overpayment associated with this communication		Commissioner is authorized to charge payment of the following fees and to d any overpayment associated with this communication or during the pendency s application to deposit account 23-3050. This sheet is provided in duplicate.
		The foregoing amount due.
		Any additional filing fees required, including fees for the presentation of extra claims under 37 C.F.R. 1.16.

The state of the s

- Any additional patent application processing fees under 37 C.F.R. 1.17 or 1.20(d).
- The Commissioner is hereby requested to grant an extension of time for the appropriate length of time, should one be necessary, in connection with this filing or any future filing submitted to the U.S. Patent and Trademark Office in the above-identified application during the pendency of this application. The Commissioner is further authorized to charge any fees related to any such extension of time to deposit account 23-3050. This sheet is provided in duplicate.

SHOULD ANY DEFICIENCIES APPEAR with respect to this application, including deficiencies in payment of fees, missing parts of the application or otherwise, the United States Patent and Trademark Office is respectfully requested to promptly notify the undersigned.

Date: Feb 28, 2002

Scott E. Scioli

Registration No. 47,930

Total & Secli

Woodcock Washburn LLP One Liberty Place - 46th Floor Philadelphia PA 19103 Telephone: (215) 568-3100

Facsimile: (215) 568-3439

©2001 WW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of:

Havkin-Frenkel, et al.

Serial No.: Not assigned yet

Group Art Unit: Not assigned yet

Filing Date: Herewith

Examiner: Not assigned yet

For: Vanillin Biosynthetic Pathway Enzyme From Vanilla Planifolia

Assistant Commissioner for Patents Washington, D.C. 20231

EXPRESS MAIL LABEL NO: EL719246398US DATE OF DEPOSIT: February 28, 2002

STATEMENT TO SUPPORT FILING AND SUBMISSION IN ACCORDANCE WITH 37 CFR §§ 1.821 THROUGH 1.825

I hereby state, in accordance with the requirements of 37 C.F.R. §1.821(f), that the contents of the paper and computer readable copies of the Sequence Listing, submitted in accordance with 37 CFR §1.821(c) and (e), respectively are the same.
I hereby state that the submission filed in accordance with 37 CFR §1.821(g) does not include new matter.
I hereby state that the submission filed in accordance with 37 CFR §1.821(h) does not include new matter or go beyond the disclosure in the international application as filed.
I hereby state that the amendments, made in accordance with 37 CFR §1.825(a), included in the substitute sheet(s) of the Sequence Listing are supported in the application, as filed, at pages I hereby state that the substitute sheet(s) of the Sequence Listing does (do) not include new matter.
I hereby state that the substitute copy of the computer readable form, submitted in accordance with 37 CFR §1.825(b), is the same as the amended Sequence Listing.

DOCK	XET NO.: DMCI-0099	- 2 -	PATENT
	I hereby state that the substitute accordance with 37 CFR §1.8	1.2	iter readable form, submitted in all data to that originally filed.
Date:	Feb 28, 2002	Scott E Scioli	E. Sioli

Registration No. 47,930

Woodcock Washburn LLP One Liberty Place - 46th Floor Philadelphia PA 19103 Telephone: (215) 568-3100

Facsimile: (215) 568-3439

© 2001 WW